Aims: To evaluate the impact of bioresorbable vascular scaffold (BRS) implantation
technique on post-procedural quantitative coronary angiography (QCA) parameters in ST …

Objectives To report 1‐year clinical outcomes of bioresorbable vascular scaffold (BVS) in
acute coronary syndromes (ACS) population. Background BVS use has rapidly extended to …

Bioresorbable vascular scaffolds (BVS) have the potential to start new era in interventional
cardiology. First clinical studies in stable coronary artery disease have demonstrated a good …

Aims We evaluated the feasibility and the acute performance of the everolimus-eluting
bioresorbable vascular scaffolds (BVS) for the treatment of patients presenting with ST …

Aims: Registry data have suggested higher than anticipated rates of scaffold thrombosis
following bioresorbable vascular scaffold (BVS) implantation. We examined early neointimal …

Objective of this study was to assess the clinical performance of bioresorbable vascular
scaffold (BVS) compared to everolimus-eluting stent (EES) in subjects with ST-segment …

Despite the withdrawal of the ABSORB bioresorbable vascular scaffold (BVS) from clinical
use, it is necessary to continue observation of BVS-treated patients. The purpose was to …

Background Bioresorbable vascular scaffolds (BVS) represent an exciting and novel
coronary intervention technology. BVS implantation could play an important role in the acute …

Background: Current revascularisation guidelines recommend coronary stenting with either
a bare metal stent or a drug eluting stent. The results of bioresorbable vascular scaffold …

Background/aims Drug eluting stent (DES) decrease the risk of restenosis by reducing the
neointimal response. However, DES may impair strut coverage, and this has been …